ethyl 4-butylpiperidine-4-carboxylate | 312638-85-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: ethyl 4-butylpiperidine-4-carboxylate
• 英文别名: Ethyl 4-butylisonipecotate
• CAS: 312638-85-0
• 化学式: C₁₂H₂₃NO₂
• 分子量: 213.32
• InChiKey: ZEXMSVFUQDDCLC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  15
• 可旋转键数：
  6
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.92
• 拓扑面积：
  38.3
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  ethyl 4-butylpiperidine-4-carboxylate 在 双氧水 、 溶剂黄146 作用下， 以 二氯甲烷 、 水 、 乙腈 为溶剂， 反应 1.5h， 生成 [4-Ethoxycarbonyl-4-(3-oxobutyl)piperidin-1-ium-1-yl]-trifluoroboranuide
  参考文献：
  名称：

  Remote Oxidation of Aliphatic C–H Bonds in Nitrogen-Containing Molecules

  摘要：

  Nitrogen heterocycles are ubiquitous in natural products and pharmaceuticals. Herein, we disclose a nitrogen complexation strategy that employs a strong Bronsted acid (HBF4) or an azaphilic Lewis acid (BF3) to enable remote, non-directed C(sp(3))-H oxidations of tertiary, secondary, and primary amine- and pyridine-containing molecules with tunable iron catalysts. Imides resist oxidation and promote remote functionalization.

  DOI：

  10.1021/jacs.5b10299
• 作为产物：
  描述：

  1-(tert-butyl) 4-ethyl 4-butylpiperidine-1,4-dicarboxylate 在 盐酸 作用下， 以 1,4-二氧六环 为溶剂， 以90%的产率得到ethyl 4-butylpiperidine-4-carboxylate
  参考文献：
  名称：

  Remote Oxidation of Aliphatic C–H Bonds in Nitrogen-Containing Molecules

  摘要：

  Nitrogen heterocycles are ubiquitous in natural products and pharmaceuticals. Herein, we disclose a nitrogen complexation strategy that employs a strong Bronsted acid (HBF4) or an azaphilic Lewis acid (BF3) to enable remote, non-directed C(sp(3))-H oxidations of tertiary, secondary, and primary amine- and pyridine-containing molecules with tunable iron catalysts. Imides resist oxidation and promote remote functionalization.

  DOI：

  10.1021/jacs.5b10299

文献信息

• COMPOUND WITH SEROTONINERGIC ACTIVITY, PROCESS FOR PREPARING IT AND PHARMACEUTICAL COMPOSITION COMPRISING IT
  申请人：Alisi Maria Alessandra

  公开号：US20110160201A1

  公开（公告）日：2011-06-30

  Compound of formula (I) in which R1, R2 and R3 are defined in the following description, and the pharmaceutically acceptable acid-addition or base-addition salts thereof. The invention also relates to a process and an intermediate for preparing it, and to a pharmaceutical composition comprising it. The invention also relates to the use of a novel 2H-pyrrolo[3,4-c]quinoline compound for preparing a pharmaceutical composition that is active in the treatment of disturbances of the serotoninergic system.

  公式（I）的复合物，其中R1、R2和R3的定义如下所述，并且其药学上可接受的酸加成物或碱加成物盐。本发明还涉及一种制备它的过程和中间体，以及包含它的制药组合物。本发明还涉及使用一种新的2H-吡咯并[3,4-c]喹啉化合物制备具有治疗5-羟色胺系统紊乱活性的制药组合物。
• Compound with serotoninergic activity, process for preparing it and pharmaceutical composition comprising it
  申请人：Alisi Maria Alessandra

  公开号：US08686147B2

  公开（公告）日：2014-04-01

  Compound of formula (I) in which R1, R2 and R3 are defined in the following description, and the pharmaceutically acceptable acid-addition or base-addition salts thereof. The invention also relates to a process and an intermediate for preparing it, and to a pharmaceutical composition comprising it. The invention also relates to the use of a novel 2H-pyrrolo[3,4-c]quinoline compound for preparing a pharmaceutical composition that is active in the treatment of disturbances of the serotoninergic system.

  公式(I)的化合物，其中R1、R2和R3的定义如下所述，并且其药学上可接受的酸加成物或碱加成物盐。本发明还涉及制备该化合物的过程和中间体，以及包含该化合物的药物组合物。本发明还涉及使用一种新型2H-吡咯并[3,4-c]喹啉化合物制备对5-羟色胺系统干扰具有活性的药物组合物。
• THERAPEUTIC COMPOUNDS AND COMPOSITIONS
  申请人：AGIOS PHARMACEUTICALS, INC

  公开号：US20150336931A1

  公开（公告）日：2015-11-26

  Compounds of general formula I: and compositions comprising compounds of general formula I that modulate pyruvate kinase are described herein. Also described herein are methods of using the compounds that modulate pyruvate kinase in the treatment of diseases.

  本文描述了通式I化合物和包含通式I化合物的组合物，这些化合物调节丙酮酸激酶。本文还描述了使用调节丙酮酸激酶的化合物治疗疾病的方法。